Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Key Developments in Health: Novo Nordisk's Wegovy, Zevra's Breakthrough, and More
Recent health news highlights include: EMA endorses Novo Nordisk's Wegovy for heart failure in obesity, FDA approves Zevra Therapeutics' treatment for a rare genetic disorder, FTC sues pharmacy benefit managers over insulin pricing, U.N. official suggests mpox in Burundi can be tackled within weeks, Sanofi's tolebrutinib shows promise in MS, Missouri healthcare worker contracts bird flu, FDA approves AstraZeneca's nasal spray flu vaccine, early studies show potential in rejuvenating older eggs for IVF and preventing newborn jaundice, U.S. appeals court revives lawsuit against Medicare drug price negotiation, and FDA approves Sanofi's Sarclisa for multiple myeloma treatment.
Regeneron/Sanofi Dupixent endorsed in EU for eosinophilic esophagitis for children
The article discusses the implementation of a Server-Side Rendering (SSR) service entry point, identified by the file path '/bundles/v1/views/latest/SSR-service-entry.a43029b098f75e2757ed.js'.
Dupixent recommended for EU approval by CHMP to treat eosinophilic esophagitis in children aged 1 to 11 years
Sanofi announced CHMP's positive opinion recommending Dupixent's expanded approval in the EU for eosinophilic esophagitis (EoE) in children aged 1 to 11 years. The recommendation is based on the EoE KIDS phase 3 study, showing Dupixent's efficacy in histological disease remission and safety consistent with its profile in adults and adolescents. The European Commission is expected to make a final decision soon.
Breaking Health News: Major Drug Approvals and Controversies
Novo Nordisk's Wegovy endorsed for heart failure in obese patients. FDA approves Zevra Therapeutics' treatment for a rare genetic disorder. FTC sues pharmacy benefit managers over insulin prices. Sanofi's multiple sclerosis drug tolebrutinib shows 31% delay in disease progression. Advances in flu vaccines, IVF, and jaundice prevention.
Type 1 Diabetes (T1D) Market Research Report 2032
The global Type 1 Diabetes (T1D) market, valued at $6.5 billion in 2023, is projected to grow to $11.3 billion by 2032, driven by increasing diabetes prevalence, technological advancements, and rising healthcare expenditure. Innovations like CGM systems and artificial pancreas devices enhance patient outcomes. Insulin therapy remains central, with advancements in delivery methods and digital health integration. Regional growth is led by North America, with Asia Pacific showing rapid expansion. Challenges include treatment costs and access, with efforts underway to improve affordability and equity.
Personalized Precision Medicine Market Share | 2031 Forecast
The global Personalized Precision Medicine Market report offers detailed segmentation and strategic guidance, covering manufacturers, regions, product categories, and applications. Key insights include market evolution, current conditions, future projections, and analysis of key players like Agilent Technologies, Biogen, Johnson & Johnson, and Novartis. The report aids stakeholders in navigating market dynamics and capitalizing on opportunities.
Major Updates in Health: Drug Approvals, Legal Battles, and Health Innovations
Recent health news includes EMA endorsing Novo Nordisk's Wegovy for heart failure in obese individuals, FDA approving Zevra Therapeutics' treatment for a rare genetic disorder, and FTC suing major pharmacy benefit managers over insulin price manipulation. Other updates cover Sanofi's MS drug trial success, efforts to end mpox in Burundi, advancements in older egg IVF, and FDA approval of AstraZeneca's nasal spray flu vaccine.
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of
FDA approves Sarclisa (isatuximab) in combination with VRd for newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant, based on IMROZ phase 3 study showing significant PFS improvement. This marks Sarclisa's third indication and first for newly diagnosed patients, reflecting Sanofi's commitment to addressing critical care gaps in multiple myeloma.
Sanofi says tolebrutinib drug delayed progressive MS by 31%
The article discusses the use of SSR (Server-Side Rendering) in web development, focusing on its implementation through a specific JavaScript bundle for enhanced performance and user experience.
Sarclisa approved in the US as the first anti-CD38 therapy in combination with VRd for newly diagnosed multiple myeloma patients not eligible for transplant
Sarclisa approved in the US as the first anti-CD38 therapy in combination with VRd for newly diagnosed multiple myeloma patients not eligible for transplant, significantly improving progression-free survival.
© Copyright 2025. All Rights Reserved by MedPath